Mission Bio

/ 400 E Jamie Ct, Suite 100

CA 94080 South San Francisco

US

Mission Bio

Foundation date

2012

Sector

#Pharma

Subsector

Mission Bio unlocks the ground truth of cancer through response, relapse, and remission with its Tapestri Platform, powered by single-cell multi-omics. As the first and only to analyze genotype and phenotype simultaneously in single cells, the Tapestri Platform can help unravel the inherent complexity of cancer. Discover how Tapestri enables accurate characterization of your cell and gene therapy candidates for safer and more effective therapeutic strategies. We partner with pharma and biopharma companies across advanced therapy development programs to implement proven single-cell multi-omics capabilities into discovery, translational, and clinical research efforts. Learn more about our Pharma Assay Development services.

Upcoming events

Latest news

  • Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China

    1 day ago

  • Celyad announces management change

    Friday December 1st 2023

  • Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States

    Thursday November 30th 2023